Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12207333rdf:typepubmed:Citationlld:pubmed
pubmed-article:12207333lifeskim:mentionsumls-concept:C0312740lld:lifeskim
pubmed-article:12207333lifeskim:mentionsumls-concept:C0007587lld:lifeskim
pubmed-article:12207333lifeskim:mentionsumls-concept:C0021745lld:lifeskim
pubmed-article:12207333lifeskim:mentionsumls-concept:C0070410lld:lifeskim
pubmed-article:12207333lifeskim:mentionsumls-concept:C1333877lld:lifeskim
pubmed-article:12207333lifeskim:mentionsumls-concept:C1539477lld:lifeskim
pubmed-article:12207333lifeskim:mentionsumls-concept:C1704259lld:lifeskim
pubmed-article:12207333lifeskim:mentionsumls-concept:C1705987lld:lifeskim
pubmed-article:12207333lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:12207333lifeskim:mentionsumls-concept:C1546857lld:lifeskim
pubmed-article:12207333lifeskim:mentionsumls-concept:C0205227lld:lifeskim
pubmed-article:12207333lifeskim:mentionsumls-concept:C0332291lld:lifeskim
pubmed-article:12207333pubmed:issue9lld:pubmed
pubmed-article:12207333pubmed:dateCreated2002-9-3lld:pubmed
pubmed-article:12207333pubmed:abstractTextActivation of resting T cells usually leads to their proliferation and differentiation into effector cells and a subsequent decline following elimination of the antigen. A situation of excessive antigen density may result in T cell receptor (TCR)-induced deletion of T effector cells, a process termed antigen-induced cell death (AgICD). Previous studies indicate that AgICD of cytotoxic T cells may be induced by either of the two key cytotoxic processes, granule exocytosis, including perforin and granzymes, or the Fas ligand (FasL)/Fas pathway. By using in vitro-polyclonally activated or ex vivo-derived virus-induced T cell populations from mice with mutations or targeted gene defects in one or more components of the two key cytolytic pathways we now show that TCR-induced apoptosis is only impaired in the absence of FasL and/or Fas, but not in the absence of perforin and/or granzymes. Furthermore, antibody-blockage of FasL alone is sufficient to inhibit early T cell death. Inhibition of both, FasL and tumor necrosis factor (TNF-alpha) is required to abrogate late apoptosis by AgICD. The fact that antibodies to IFN-gamma also inhibit AgICD suggests that the perforin plus granzyme-independent and FaSL and/or TNF-alpha facilitated process of AgICD of T effector cells is tightly regulated by endogenous IFN-gamma.lld:pubmed
pubmed-article:12207333pubmed:languageenglld:pubmed
pubmed-article:12207333pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12207333pubmed:citationSubsetIMlld:pubmed
pubmed-article:12207333pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12207333pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12207333pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12207333pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12207333pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12207333pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12207333pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12207333pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12207333pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12207333pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12207333pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12207333pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12207333pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12207333pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12207333pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12207333pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12207333pubmed:statusMEDLINElld:pubmed
pubmed-article:12207333pubmed:monthSeplld:pubmed
pubmed-article:12207333pubmed:issn0014-2980lld:pubmed
pubmed-article:12207333pubmed:authorpubmed-author:KörnerHeinric...lld:pubmed
pubmed-article:12207333pubmed:authorpubmed-author:SimonMarkus...lld:pubmed
pubmed-article:12207333pubmed:authorpubmed-author:BalkowSandraSlld:pubmed
pubmed-article:12207333pubmed:authorpubmed-author:SobekVeraVlld:pubmed
pubmed-article:12207333pubmed:issnTypePrintlld:pubmed
pubmed-article:12207333pubmed:volume32lld:pubmed
pubmed-article:12207333pubmed:ownerNLMlld:pubmed
pubmed-article:12207333pubmed:authorsCompleteYlld:pubmed
pubmed-article:12207333pubmed:pagination2490-9lld:pubmed
pubmed-article:12207333pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:12207333pubmed:meshHeadingpubmed-meshheading:12207333...lld:pubmed
pubmed-article:12207333pubmed:meshHeadingpubmed-meshheading:12207333...lld:pubmed
pubmed-article:12207333pubmed:meshHeadingpubmed-meshheading:12207333...lld:pubmed
pubmed-article:12207333pubmed:meshHeadingpubmed-meshheading:12207333...lld:pubmed
pubmed-article:12207333pubmed:meshHeadingpubmed-meshheading:12207333...lld:pubmed
pubmed-article:12207333pubmed:meshHeadingpubmed-meshheading:12207333...lld:pubmed
pubmed-article:12207333pubmed:meshHeadingpubmed-meshheading:12207333...lld:pubmed
pubmed-article:12207333pubmed:meshHeadingpubmed-meshheading:12207333...lld:pubmed
pubmed-article:12207333pubmed:meshHeadingpubmed-meshheading:12207333...lld:pubmed
pubmed-article:12207333pubmed:meshHeadingpubmed-meshheading:12207333...lld:pubmed
pubmed-article:12207333pubmed:meshHeadingpubmed-meshheading:12207333...lld:pubmed
pubmed-article:12207333pubmed:meshHeadingpubmed-meshheading:12207333...lld:pubmed
pubmed-article:12207333pubmed:meshHeadingpubmed-meshheading:12207333...lld:pubmed
pubmed-article:12207333pubmed:meshHeadingpubmed-meshheading:12207333...lld:pubmed
pubmed-article:12207333pubmed:meshHeadingpubmed-meshheading:12207333...lld:pubmed
pubmed-article:12207333pubmed:meshHeadingpubmed-meshheading:12207333...lld:pubmed
pubmed-article:12207333pubmed:meshHeadingpubmed-meshheading:12207333...lld:pubmed
pubmed-article:12207333pubmed:meshHeadingpubmed-meshheading:12207333...lld:pubmed
pubmed-article:12207333pubmed:meshHeadingpubmed-meshheading:12207333...lld:pubmed
pubmed-article:12207333pubmed:meshHeadingpubmed-meshheading:12207333...lld:pubmed
pubmed-article:12207333pubmed:meshHeadingpubmed-meshheading:12207333...lld:pubmed
pubmed-article:12207333pubmed:meshHeadingpubmed-meshheading:12207333...lld:pubmed
pubmed-article:12207333pubmed:meshHeadingpubmed-meshheading:12207333...lld:pubmed
pubmed-article:12207333pubmed:meshHeadingpubmed-meshheading:12207333...lld:pubmed
pubmed-article:12207333pubmed:meshHeadingpubmed-meshheading:12207333...lld:pubmed
pubmed-article:12207333pubmed:year2002lld:pubmed
pubmed-article:12207333pubmed:articleTitleAntigen-induced cell death of T effector cells in vitro proceeds via the Fas pathway, requires endogenous interferon-gamma and is independent of perforin and granzymes.lld:pubmed
pubmed-article:12207333pubmed:affiliationMax-Planck-Institut für Immunbiologie, Freiburg, Germany.lld:pubmed
pubmed-article:12207333pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12207333pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:12207333pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:14102entrezgene:pubmedpubmed-article:12207333lld:entrezgene
entrez-gene:14103entrezgene:pubmedpubmed-article:12207333lld:entrezgene
entrez-gene:15978entrezgene:pubmedpubmed-article:12207333lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:12207333lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:12207333lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:12207333lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12207333lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12207333lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12207333lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12207333lld:pubmed